SAN MATEO, Calif., May 5, 2009 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), announced the initiation of another clinical study for PTI-188, an investigational drug intended to treat a lethal form of skin cancer called metastatic melanoma (MM). This study follows the release of promising data in an earlier Phase I study for PTI-188, published at the Meeting of the Society for Nuclear Medicine.
